Abeona Therapeutics
ABEO
95 hedge funds and large institutions have $198M invested in Abeona Therapeutics in 2025 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 18 closing their positions.
504% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $2.43M
158% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 12
133% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 18
83% more capital inflows, than outflows
Capital inflows: $72.4M | Capital outflows: $39.5M
34% more funds holding
Funds holding: 71 → 95 (+24)
7.08% more ownership
Funds ownership: 61.14% → 68.23% (+7.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.1M |
| 2 |
Boone Capital Management
Atlanta,
Georgia
|
+$7.14M |
| 3 |
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.22M |
| 4 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.89M |
| 5 |
Morgan Stanley
New York
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$8.6M |
| 2 |
Laurion Capital Management
New York
|
-$5.87M |
| 3 |
Suvretta Capital Management
New York
|
-$5.75M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.02M |
| 5 |
Millennium Management
New York
|
-$3.15M |
ABEO Hedge Fund Activity: Q2 2025 in Review
95 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2025, worth a combined $198M — up 40% from $141M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ABEO positions and 18 closed out — a net gain of 24 holders — while 31 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $14.1M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $8.6M sold.
- 95 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2025, up from 71 in Q1 2025.
- Funds reported $198M of Abeona Therapeutics stock for Q2 2025, up 40% quarter-over-quarter.
- 42 funds opened new Abeona Therapeutics positions in Q2 2025 and 18 closed out, a net change of +24 holders.
- The largest Abeona Therapeutics buyer in Q2 2025 was BlackRock, an estimated $14.1M added.
- The largest Abeona Therapeutics seller in Q2 2025 was Rosalind Advisors, an estimated $8.6M sold.
Based on aggregated 13F filings for Q2 2025.